Vaxcyte Files Routine 8-K, Confirms Registration Details

TL;DR

**Vaxcyte filed a routine 8-K, no new news for traders.**

AI Summary

Vaxcyte, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024. This filing is a routine update, primarily confirming the company's current registration details, including its Delaware incorporation, Commission File Number 001-39323, and its common stock trading on The Nasdaq Stock Market LLC under the symbol PCVX. For investors, this filing is a standard compliance document and does not contain new material financial or operational information that would immediately impact stock valuation.

Why It Matters

This filing is a standard regulatory update, confirming Vaxcyte's basic corporate information and its listing on Nasdaq, which is important for maintaining transparency and compliance but doesn't signal new business developments.

Risk Assessment

Risk Level: low — This 8-K is a standard compliance filing and does not introduce new risks or material changes to the company's operations or financial standing.

Analyst Insight

A smart investor would recognize this as a routine compliance filing and not indicative of any immediate change in Vaxcyte's business operations or financial health, thus requiring no immediate action based solely on this document.

Key Numbers

• 001-39323 — Commission File Number (Vaxcyte's SEC file number)
• 46-4233385 — IRS Employer Identification No. (Vaxcyte's IRS number)
• 825 Industrial Road, Suite 300, San Carlos, California, 94070 — Business Address (Vaxcyte's principal executive offices)
• (650) 837-0111 — Telephone Number (Vaxcyte's business phone number)
• 2024-01-30 — Date of Report (earliest event reported in the filing)

Key Players & Entities

• Vaxcyte, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Vaxcyte, Inc.
• The Nasdaq Stock Market LLC (company) — exchange where Vaxcyte's common stock is registered
• PCVX (company) — trading symbol for Vaxcyte, Inc. common stock

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq
• $64.00 — per share, at a price to the public of $64.00 per share, and pre-funded warrants to p
• $63.999 — ommon stock at a price to the public of $63.999 per pre-funded warrant, which is the pr
• $60.64 — common stock from Vaxcyte at a price of $60.64 per share and the pre-funded warrants a
• $60.639 — d the pre-funded warrants at a price of $60.639 per pre-funded warrant. Vaxcyte also gr
• $816.5 m — se additional shares, is expected to be $816.5 million, after deducting underwriting dis

Filing Documents

• d752729d8k.htm (8-K) — 30KB
• d752729dex11.htm (EX-1.1) — 221KB
• d752729dex41.htm (EX-4.1) — 66KB
• d752729dex51.htm (EX-5.1) — 12KB
• g752729g0131011016866.jpg (GRAPHIC) — 2KB
• 0001193125-24-021084.txt ( ) — 536KB
• pcvx-20240130.xsd (EX-101.SCH) — 3KB
• pcvx-20240130_lab.xml (EX-101.LAB) — 18KB
• pcvx-20240130_pre.xml (EX-101.PRE) — 11KB
• d752729d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 1.1 Underwriting Agreement, dated January 30, 2024 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Cooley LLP 23.1 Consent of Cooley LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: January 31, 2024 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR